Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 3/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | HTR2B | P41595 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | KIT | P10721 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4584366 | 0.84 | KDM4E (0.64) | MEN1KMT2AKDM4ENPSR1ALDH1A1 | |
| SCHEMBL1316827 | 0.82 | NAMPT (0.62) | NAMPTCYP3A4CYP2D6MEN1KMT2A | |
| SCHEMBL13621149 | 0.82 | MEN1 (0.71) | NAMPTMEN1KMT2AKDM4EHTR2C | |
| SCHEMBL12801912 | 0.82 | MEN1 (0.51) | MEN1KMT2AKDM4EHTR2CHTR2B | |
| SCHEMBL29682382 | 0.82 | MEN1 (0.51) | MEN1KMT2AKDM4EHTR2CHTR2B | |
| SCHEMBL5956394 | 0.82 | TP53 (0.59) | MEN1KMT2AHTR2CHTR2BKIT | |
| SCHEMBL32660728 | 0.81 | KCNH2 (0.51) | NAMPTMEN1KMT2AKDM4EHTR2C | |
| Hydrochloric Acid SCHEMBL28550900 | 0.81 | TP53 (0.58) | MEN1KMT2AHTR2CHTR2BKIT | |
| SCHEMBL1668842 | 0.79 | KIT (0.49) | MEN1KMT2AKDM4EHTR2CHTR2B | |
| SCHEMBL654167 | 0.78 | SMN1; SMN2 (0.60) | MEN1KMT2AALDH1A1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118234712-A | Compounds and their use for the treatment of mood and behavioral disorders | 株式会社纽若梵提 | 2024-06-21 | — | — | CN | claimed |
| CN-118234712-A | Compounds and their use for the treatment of mood and behavioral disorders | 株式会社纽若梵提 | 2024-06-21 | — | — | CN | disclosed |
| US-20170267717-A1 | Novel method for the production of 18F-labeled active esters and their application exemplified by the preparation of a PSMA-specific PET-tracer | MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2017-09-21 | — | — | US | disclosed |
| CN-1100054-C | Process for preparing HIV protease inhibitors from (2S) -4-picolyl-2-piperazine-tert-butylcarboxamide | MERCK & CO INC (US) | 2003-01-29 | — | — | CN | disclosed |
| EP-0815101-B1 | PROCESS TO MAKE HIV PROTEASE INHIBITOR FROM 2(S)-4-PICOLYL-2-PIPERAZINE-t-BUTYLCARBOXAMIDE | MERCK & CO INC (US) | 1999-07-07 | — | — | EP | disclosed |
| CN-1183779-A | Process for preparing HIV protease inhibitors from (2S) -4-picolyl-2-piperazine-tert-butylcarboxamide | MERCK & CO INC (US) | 1998-06-03 | — | — | CN | disclosed |
| EP-0815101-A1 | PROCESS TO MAKE HIV PROTEASE INHIBITOR FROM 2(S)-4-PICOLYL-2-PIPERAZINE-t-BUTYLCARBOXAMIDE | Merck & Co., Inc. (US) | 1998-01-07 | — | — | EP | disclosed |
| US-5618937-A | HEATING FOR AT LEAST ONE HOUR MIXTURE OF ONE EQUIVALENT OF 4-PICOLYL-2-PIPERAZINE-TERT-BUTYLCARBOXAMIDE WITH ONE EQUIVALENT OF SPECIFIED EPOXIDE, DEBLOCKING WITH STRONG ACID, NEUTRALIZING | MERCK & CO., INC. (US) | 1997-04-08 | — | — | US | disclosed |
| US-5612484-A | EFFICIENCY, SIMPLIFICATION | MERCK & CO., INC. (US) | 1997-03-18 | — | — | US | disclosed |
| WO-1996036629-A1 | PROCESS FOR MAKING HIV PROTEASE INHIBITORS | MERCK & CO., INC. (US) | 1996-11-21 | — | — | WO | disclosed |
| WO-1996028439-A1 | PROCESS TO MAKE HIV PROTEASE INHIBITOR FROM 2(S)-4-PICOLYL-2-PIPERAZINE-t-BUTYLCARBOXAMIDE | MERCK & CO., INC. (US) | 1996-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170267717-A1 | Novel method for the production of 18F-labeled active esters and their application exemplified by the preparation of a PSMA-specific PET-tracer | FGB, F13B, FAP | NAMPT 1462/4885CYP3A4 1540/4885CYP2D6 2567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.